Neuroimmunophilin ligands in the treatment of Parkinson's disease

Bruce G. Gold, John Nutt

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Parkinson's disease treatment can be divided into three categories: symptomatic, protective and restorative. This review focuses on the restorative and neuroprotective actions of a new class of potential therapeutic agents, neuroimmunophilin ligands. To date, however, short-term treatments with two such compounds in a non-human primate model and in patients with Parkinson's disease have been disappointing.

Original languageEnglish (US)
Pages (from-to)82-86
Number of pages5
JournalCurrent Opinion in Pharmacology
Volume2
Issue number1
DOIs
StatePublished - Feb 1 2002

Fingerprint

Parkinson Disease
Ligands
Primates
Therapeutics

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Neuroimmunophilin ligands in the treatment of Parkinson's disease. / Gold, Bruce G.; Nutt, John.

In: Current Opinion in Pharmacology, Vol. 2, No. 1, 01.02.2002, p. 82-86.

Research output: Contribution to journalArticle

@article{56ee86b79ac44868956b4835f81440cf,
title = "Neuroimmunophilin ligands in the treatment of Parkinson's disease",
abstract = "Parkinson's disease treatment can be divided into three categories: symptomatic, protective and restorative. This review focuses on the restorative and neuroprotective actions of a new class of potential therapeutic agents, neuroimmunophilin ligands. To date, however, short-term treatments with two such compounds in a non-human primate model and in patients with Parkinson's disease have been disappointing.",
author = "Gold, {Bruce G.} and John Nutt",
year = "2002",
month = "2",
day = "1",
doi = "10.1016/S1471-4892(01)00125-4",
language = "English (US)",
volume = "2",
pages = "82--86",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Neuroimmunophilin ligands in the treatment of Parkinson's disease

AU - Gold, Bruce G.

AU - Nutt, John

PY - 2002/2/1

Y1 - 2002/2/1

N2 - Parkinson's disease treatment can be divided into three categories: symptomatic, protective and restorative. This review focuses on the restorative and neuroprotective actions of a new class of potential therapeutic agents, neuroimmunophilin ligands. To date, however, short-term treatments with two such compounds in a non-human primate model and in patients with Parkinson's disease have been disappointing.

AB - Parkinson's disease treatment can be divided into three categories: symptomatic, protective and restorative. This review focuses on the restorative and neuroprotective actions of a new class of potential therapeutic agents, neuroimmunophilin ligands. To date, however, short-term treatments with two such compounds in a non-human primate model and in patients with Parkinson's disease have been disappointing.

UR - http://www.scopus.com/inward/record.url?scp=0036462452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036462452&partnerID=8YFLogxK

U2 - 10.1016/S1471-4892(01)00125-4

DO - 10.1016/S1471-4892(01)00125-4

M3 - Article

C2 - 11786313

AN - SCOPUS:0036462452

VL - 2

SP - 82

EP - 86

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 1

ER -